Leavell Investment Management Inc. Sells 63 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Leavell Investment Management Inc. reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,392 shares of the medical research company’s stock after selling 63 shares during the period. Leavell Investment Management Inc.’s holdings in Thermo Fisher Scientific were worth $3,956,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Burt Wealth Advisors acquired a new position in shares of Thermo Fisher Scientific during the third quarter valued at about $205,000. Capital Performance Advisors LLP acquired a new position in shares of Thermo Fisher Scientific in the third quarter valued at $129,000. AIA Group Ltd increased its holdings in Thermo Fisher Scientific by 1.8% in the 3rd quarter. AIA Group Ltd now owns 17,676 shares of the medical research company’s stock valued at $10,934,000 after buying an additional 309 shares during the period. Verity Asset Management Inc. bought a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth about $283,000. Finally, Portside Wealth Group LLC lifted its stake in Thermo Fisher Scientific by 2.7% during the third quarter. Portside Wealth Group LLC now owns 11,495 shares of the medical research company’s stock worth $7,110,000 after purchasing an additional 303 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Down 0.7 %

Thermo Fisher Scientific stock opened at $551.74 on Friday. The stock has a market capitalization of $211.04 billion, a PE ratio of 34.59, a price-to-earnings-growth ratio of 3.70 and a beta of 0.79. Thermo Fisher Scientific Inc. has a twelve month low of $437.26 and a twelve month high of $627.88. The company has a 50 day moving average of $593.95 and a 200-day moving average of $583.63. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same quarter in the prior year, the firm posted $5.69 EPS. The business’s revenue was up .2% on a year-over-year basis. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is 9.78%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $558.12, for a total value of $5,581,200.00. Following the completion of the transaction, the chief executive officer now directly owns 33,608 shares in the company, valued at $18,757,296.96. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $558.12, for a total value of $5,581,200.00. Following the completion of the transaction, the chief executive officer now owns 33,608 shares of the company’s stock, valued at $18,757,296.96. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now owns 12,736 shares of the company’s stock, valued at $7,134,197.76. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,150 shares of company stock valued at $15,676,125. 0.34% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TMO. Raymond James raised their target price on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Robert W. Baird reduced their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Redburn Atlantic assumed coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They set a “buy” rating and a $680.00 target price on the stock. Finally, Evercore ISI cut their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $649.33.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.